Lyell Immunopharma, Inc.

Curative cell-based immunotherapies for cancer

Lyell was founded in 2018 in Seattle, Washington based on insights from investigators Crystal Mackall, Stan Riddell, MD and David Baker (with Scott Boyken, Bobby Langan, and Marc Lajoie of the IPD). Under the leadership of Rick Klausner, Lyell is developing cell-based immunotherapies focused on CAR-Ts and solid tumors. Lyell has technology to control of T-cell exhaustion, the critical path to successful therapy. Lyell further hopes to control of on-target, off-cancer, highly specific action by T-cells to enhance therapy and reduce side-effects.